IGC

IGC Pharma (IGC)

About IGC Pharma (IGC)

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

Details

Daily high

$0.34

Daily low

$0.32

Price at open

$0.33

52 Week High

$0.50

52 Week Low

$0.25

Market cap

31.0M

Dividend yield

0.00%

Volume

760,289

Avg. volume

557,956

P/E ratio

-4.29

IGC Pharma News